1 (Sphk 1) and 2 catalyze the formation of S1P from Sph and adenosine triphosphate (ATP). The bioactive lipid metabolite S1P is involved in the control of diverse cellular processes in different cell types, including cell proliferation, cell survival and migration, cytoskeletal rearrangements, cell adhesion and inflammation, as well as angiogenesis. [5] [6] [7] [8] [9] [10] S1P not only exerts this wide range of effects predominantly by binding to 1 of the 5 known G-protein-coupled membrane receptors (S1PR 1 -S1PR 5 ) 11 but also acts as a second messenger inside cells. 12 The concentrations of S1P are high in blood and lymph fluid, but low in tissues. Maintenance of a steep blood-to-tissue S1P gradient is of critical importance for trafficking and immune surveillance by adaptive immune cells, particularly T cells. 13 Intracellular S1P levels are low in many cell types and are tightly regulated via the irreversible cleavage of S1P by S1P-lyase or via dephosphorylation to Sph by S1P-phosphatases. 14 However, unlike most other blood cells, platelets contain high Sphk activities 15 but at the same time lack S1P-lyase activity and are therefore able to store and release high amounts of S1P. 16, 17 Erythrocytes also lack the S1P degrading machinery, but they have only low constitutive Sphk activity. 18 As a consequence, platelets were originally considered to be the major source of blood S1P. However, studies showing that thrombocytopenic mice having normal plasma S1P concentrations have challenged this concept. 13, 17 Therefore, although platelets store and release S1P, red blood cells and also vascular endothelial cells are currently considered to be the major cellular contributors of plasma S1P, 19 establishing and maintaining the steep blood-to-tissue S1P gradient. 20 Hence, given its redundancy in maintenance of blood S1P levels, the role of platelet-derived S1P still remains unclear.
Here, we addressed the importance of platelet-derived S1P for the intrinsic control of distinct platelet functions. We report that activated but not resting platelets release S1P and that Sphk2, but not Sphk1, is responsible for S1P production in platelets. Platelet S1P generation is dispensable for S1P homeostasis in blood; however, it is essential for cell autonomous control of platelet activation. Correspondingly, we demonstrate that Sphk2 null platelets produce reduced amounts of TBXA2 in response to activation and fail to aggregate normally both in vitro and in response to vascular injury in vivo, while platelet adhesion remains unaffected. We show that S1P directly initiates whole blood aggregation via S1P receptor 1 expressed by platelets and facilitates platelet aggregation in response to protease-activated receptor 4-peptide (PAR4-P) and ADP. High concentrations of exogenous S1P rescue defective aggregation of Sphk2 null platelets. Together, our findings identify S1P released by platelet Sphk2 acting via S1P receptor 1 (S1PR 1 ) as a novel cell autonomous pathway intrinsically regulating platelet functions.
Methods
Full Methods are described in the Online Data Supplement.
Animals
Specific pathogen-free wild-type (WT) C57BL/6J mice were purchased from Charles River Laboratories. Sphk1-and Sphk2-deficient mice on the C57BL/6 background were a kind gift from Andrea Huwiler, Institute of Pharmacology, University of Bern, Switzerland, whereas Sphk1-and Sphk2-deficient mice on the Balb/c background 21 were a kind gift from Novartis Institutes for Biomedical Research, Basel, Switzerland.
All mice used in the experiments were 8 to 14 weeks old and weight and sex matched. All experimental procedures performed on animals were approved by the local legislation on protection of animals (Regierung von Oberbayern, Munich).
Results

Sphk2 Is the Major Isoform in Platelets and Responsible for S1P Generation and Secretion
Several previous studies have demonstrated that platelets store and secrete S1P into the plasma, 16, 22 however, the molecular pathways involved have remained unclear. Therefore, we first focused on identifying the Sphk isoform(s) responsible for the formation and release of S1P by platelets. To achieve this, we analyzed Sphk1 and Sphk2 mutant mice. As reported previously, red blood cell and leukocyte counts were normal, whereas platelet counts were reduced in Sphk2-deficient mice, but not in Sphk1-deficient mice (on C57B6/J and Balb/c background) because of a defect in proplatelet shedding by Sphk2-deficient megakaryocytes. 23 We purified platelets from WT, Sphk1 −/− , or Sphk2 −/− mice and analyzed S1P levels in platelet lysates by liquid-chromatography/mass spectrometry. Whereas platelets lacking Sphk1 show an increase in intracellular S1P levels, S1P was hardly detectable in Sphk2-deficient platelets ( Figure 1A ). We did not find any differences in the gross platelet morphology, the number of platelet mitochondria, or in the number of specific vesicles/granules between WT and mutant mice, indicating that the inability of Sphk2-deficient platelets to synthetize and secrete S1P does not result from or lead to a disturbed organelle composition ( Figure 1B) . We also analyzed the mRNA expression of both Sphks in WT, Sphk1-and 2-deficient platelets and found that the loss of 1 Sphk isoform does not affect the expression of the other Sphk isoform (N. Urtz, unpublished data, 2007) . To further substantiate the role of both Sphk isoforms for platelet S1P synthesis and secretion, we incubated WT, Sphk1-, or Sphk2-deficient platelets with [ 3 H]-D-erythro-sphingosine and analyzed platelet supernatants for the presence of S1P by thin layer chromatography. Resting WT and Sphk1 −/− platelets each secreted low amounts of S1P into the medium. This S1P release was markedly increased in response to α-thrombin stimulation ( Figure 1C ). In contrast, platelets lacking Sphk2 failed to secrete S1P even after stimulation by α-thrombin. Taken together, these findings have 2 major implications: (1) They show that Sphk2 is the major isoform responsible for S1P generation in platelets, 
Sphk1 Is the Major Isoform in Red Blood Cells and Contributes to Plasma S1P
We next examined the role of both Sphk isoforms for S1P production in red blood cells, which are thought to be the main source of plasma S1P. To address this, we isolated red blood cells from WT, Sphk1-, or Sphk2-deficient mice and determined S1P levels by liquid-chromatography/mass spectrometry. Interestingly, red blood cells lacking Sphk2 show intracellular S1P levels similar to WT cells. In contrast, Sphk1-deficient red blood cells fail to generate S1P (Figure 2A) . We also performed Sphk activity assays in red blood cells following the addition of [
]-S1P was extracted from cell lysates and analyzed by thin layer chromatography. We could not detect any S1P in Sphk1 −/− red blood cells, whereas WT or Sphk2 −/− red blood cells revealed normal S1P generation ( Figure 2B ).
Because S1P production in platelets and red blood cells is regulated by different Sphks, we next explored how S1P production by the 2 isoforms would affect plasma S1P levels. We found that in Sphk1-deficient mice S1P plasma concentrations are reduced by about 50% when compared with WT ( Figure 2C ). This finding is consistent with data reported previously by others. 21, 24 In contrast, loss of Sphk2 did not reduce but rather yielded a moderate increase of plasma S1P levels ( Figure 2C ), a finding that is in line with previous reports. 21, 25 In red blood cells, Sphk1, but not Sphk2, is therefore essential for the catalytic conversion of Sph to S1P. The reduced plasma S1P levels in Sphk1-deficient mice support the concept that red blood cells are a main source of plasma S1P. In contrast, platelet S1P production, which depends on Sphk2, is dispensable for maintenance of S1P homeostasis in the blood. This is consistent with the low steady state release of S1P by platelets, which is increased dramatically only when platelets are activated ( Figure 1C ).
Sphk2-Deficient Platelets Release Decreased Amounts of AA and Its Metabolite Thromboxane A2
Rather than contributing to general blood S1P homeostasis, S1P synthesis by activated platelets might act locally by providing an intrinsic and cell autonomous control of platelet function in scenarios of vessel damage. To test this hypothesis, we first analyzed whether the inability to synthetize and secrete S1P might affect the capability of Sphk2 −/− platelets to release potent platelet agonists. To this end, we examined the AA release from WT, Sphk1 −/− , or Sphk2 −/− platelets after preincubation with [ 3 H]-AA. On activation with α-thrombin for the indicated time points, release of AA into the supernatants was measured ( Figure 3A ). Loss of Sphk1 had no significant effect on the release of AA (except 30 minutes after stimulation) and its metabolite TBXA2 by resting or thrombin-activated platelets when compared with WT platelets ( Figure 3B ). In contrast, release of AA, and in particular of TBXA2, was significantly reduced in activated platelets obtained from Sphk2-deficient mice compared with WT or Sphk1-deficient mice ( Figure 3A and 3B) . No difference in TBXA2 release Figure 1 . Sphingosine kinase 2 (Sphk2) is the major isoform in murine platelets. A, Intracellular sphingosine 1-phosphate (S1P) levels were assayed by liquid-chromatography/mass spectrometry from wild-type (WT), Sphk1-, and Sphk2-deficient platelets. Values represent mean±SD, n=3/group. Statistical significance was calculated using MannWhitney rank-sum test. B, Electron microscopic evaluation of WT, Sphk1-, and Sphk2-deficient platelets showing normal morphology; note the mitochondria (black arrow M) and the specific granules (black arrow SG) in the cytoplasm. Bar, 2 μm; n=5/group. C, Sphk2-deficient platelets fail to secrete S1P into the medium. H-S1P secretion from unstimulated or α-thrombin-stimulated platelets (time points indicated on the top) isolated from WT, Sphk1-, and Sphk2-deficient mice were analyzed by thin layer chromatography (TLC). Shown is an autoradiogram of a TLC plate representative of 2 independent experiments. Left, The position of was observed in response to collagen, whereas ADP did not trigger any TBXA2 generation in either WT or Sphk null platelets (N. Urtz, unpublished data, 2014).
To also define the role of platelet S1P for the release of dense granules, we measured the ATP concentration in the supernatants of platelets isolated from WT and Sphk1-or Sphk2-deficient Wild-type (WT; black bars), Sphk1-deficient (grey bars), and Sphk2-deficient (white bars) platelets were left unstimulated (0 minutes) or induced with α-thrombin, and release of AA was analyzed at the indicated time points. Shown are the mean values±SD from 1 experiment representative of 3 independent experiments; n=4/group. B, Decreased thromboxane A2 (TBXA2) release after α-thrombin activation in Sphk2-deficient platelets. WT (black bars), Sphk1-deficient (grey bars), and Sphk2-deficient (white bars) platelets were left unstimulated (0 minutes) or induced with α-thrombin, and release of TBXA2 in the supernatant was analyzed at the indicated time points. Shown are the mean values±SD; n=6/group. C, Normal adenosine triphosphate (ATP) release after α-thrombin activation. WT (black bars), Sphk1-deficient (grey bars), and Sphk2-deficient (white bars) platelets were left unstimulated (0 minutes) or induced with α-thrombin, and release of ATP in the supernatant was analyzed at the indicated time points. Shown are the mean values±SD from 1 experiment representative of 2 independent experiments, n=3/group. Statistical significances were calculated using Mann-Whitney rank-sum test. Figure 2 . Sphingosine kinase 1 (Sphk1) is the major isoform in red blood cells and regulates plasma sphingosine 1-phosphate (S1P) in mice. A, Intracellular S1P levels from wild-type (WT), Sphk1-, and Sphk2-deficient red blood cells were assayed by mass spectrometry (MS). Values represent mean±SD; n=3/group. B, Sphk activities were measured in WT (black bar), Sphk1-deficient (grey bar), and Sphk2-deficient (white bar) red blood cells in the presence of 33 P-γ-ATP. Shown is the quantification of the generation of 33 P-S1P; n=4/ group. C, S1P plasma levels in WT, Sphk1-deficient, and Sphk2-deficient mice analyzed by MS; n=3/ group. Statistical significances were calculated using Mann-Whitney rank-sum test.
by guest on July 22, 2017 http://circres.ahajournals.org/ Downloaded from mice. As demonstrated in Figure 3C , loss of Sphk2 does not impair dense granule storage or depletion but rather leads to a mild increase in ATP release in response to thrombin activation. Together our findings suggest that loss of Sphk2 in platelets is associated with a severe defect in the release of the AA metabolite TBXA2, whereas release of dense granules is not affected.
Sphk2-Deficient Platelets Accomplish Normal Adhesion In Vitro and In Vivo
We subsequently asked whether these findings translate into a defect in platelet functions. Adhesion of resting platelets to exposed extracellular matrix proteins at sites of injured vascular walls is the first step in primary hemostasis. To test the role of Sphk2-dependent S1P release in this process, we performed in vitro adhesion assays, in which isolated and fluorescently labeled platelets were perfused over chamber slides coated with different matrix proteins, including fibrinogen, von Willebrand factor, and laminin. We found that both Sphk1-and Sphk2-deficient platelets adhere normally to fibrinogen, von Willebrand factor, or laminin ( Figure 4A and 4B). Similar results were obtained when we used coating with fibrillar collagen (Online Figure I ).
To further analyze the impact of Sphk-dependent S1P generation in vivo, we next evaluated platelet adhesion to the vessel wall in response to endothelial disruption in mice. To achieve this, we induced transluminal mechanical injury of the femoral arteries using a flexible wire as described previously. 26, 27 This model is known to promote platelet adhesion in a multistep process involving collagen, von Willebrand factor, and fibrinogen. 27 Fluorescently labeled platelets from WT, Sphk1-, or Sphk2-deficient donors were infused intravenously into genotype-matched recipients. Platelet adhesion was monitored by intravital epifluorescence microscopy at different time points after denudation. Consistent with our in vitro findings, platelets lacking Sphk1 or Sphk2 adhered normally to the injured vessel wall throughout the entire observation period ( Figure 4A and 4C). Together, these data suggest that Sphk2-dependent intrinsic S1P release is dispensable for platelet adhesion in injured arteries in vivo. S1P Intrinsically Controls Platelet Aggregation via S1P Receptor S1PR 1 S1P has been reported to induce platelet shape change and aggregation, the steps ensuing platelet adhesion during thrombosis and hemostasis. 22, 28 Indeed, using impedance aggregometry of whole blood from healthy human donors, we observed that S1P provokes a weak, but significant and dosedependent aggregation of platelets. The proaggregatory effects of S1P are first seen at concentrations just above those reported in plasma and reach a maximum with the highest S1P concentration tested (50 μmol/L; Figure 5A ). Next, we examined the S1P receptor subtypes involved in S1P-induced platelet aggregation. We have previously shown that the platelet/megakaryocyte lineage predominantly expresses the S1PR subtypes S1PR 1 , as well as S1PR 2 , and S1PR 4, but not S1PR 3 or S1PR 5 29 .
SEW2781, a potent and selective S1PR 1 agonist, triggered a dose-dependent platelet aggregation similar to that observed with S1P, suggesting that S1PR 1 predominantly mediates S1P-dependent platelet aggregation, whereas other S1PRs are dispensable ( Figure 5B ). Consequently, W146, which inhibits S1PR 1 , but not the S1PR 2 antagonist JTE013, dose dependently blocked S1P-stimulated whole blood aggregation ( Figure 5C ; Online Figure II ).
We then tested whether endogenous S1P released by platelets in response to activation by prototypic platelet agonists also modulates aggregation via S1PR 1 . To address this, human whole blood was pretreated with W146 to inhibit the S1PR 1 or with vehicle alone. Inhibition of S1PR 1 led to a significant impairment of PAR4-P and ADP-triggered platelet aggregation, whereas aggregation in response to collagen remained unaffected ( Figure 5D ). Together, this indicates that Sphk2-dependent S1P acts as an intrinsic and cell autonomous regulator, facilitating platelet aggregation to PAR4 agonists and ADP but not to collagen in a process involving S1PR 1 .
Sphk2-Deficient Platelets Reveal Impaired Aggregation
Next, we further evaluated the above hypothesis that platelets intrinsically control their aggregation via Sphk2-dependent S1P generation and release. To test this, whole blood was taken from WT or Sphk1-deficient or Sphk2-deficient mice and exposed to collagen, PAR4-P, or ADP to trigger aggregation. As shown in Figure 6A , loss of Sphk2 was associated with a severe (40%) reduction in PAR4-P, as well as ADP-induced aggregation, whereas platelet aggregation in response to collagen was only moderately affected. In contrast, Sphk1-deficient platelets aggregated normally in response to all agonists tested ( Figure 6A ). These findings were consistent across different genetic backgrounds of mice (N. Urtz, unpublished data, 2011). Consistent with previous reports, 30 dilution of blood from WT mice with platelet poor plasma was not sufficient to phenocopy the defect in platelet aggregation observed in Sphk2-deficient mice (N. Urtz, unpublished data, 2011), indicating that the reduced platelet numbers in these mutants are unlikely to be responsible for their defect in PAR4-P and ADPinduced aggregation. . Sphingosine 1-phosphate (S1P) controls platelet aggregation via S1P receptor 1 (S1PR 1 ) in human blood. A, S1P triggers whole blood aggregation. Whole blood was incubated with different S1P concentrations or treated with vehicle alone as control (ctrl) and platelet aggregation was analyzed; n=10 donors. B, S1PR 1 agonist SEW2781 triggers aggregation. Whole blood was incubated with different SEW2781 concentrations or treated with vehicle alone as ctrl and platelet aggregation was analyzed; n=6 donors. C, S1PR 1 antagonism prevents S1P-induced aggregation. Blood was pretreated with different W146 concentrations or treated with vehicle alone (ctrl). Subsequent platelet aggregation was induced with S1P; n=6 donors. D, S1PR 1 affects PAR4-P and adenosine diphosphate (ADP)-induced aggregation. Whole blood was treated either with vehicle alone or with the S1PR 1 antagonist W146 (1 μmol/L), and platelet aggregation was induced with collagen (col), ADP, and proteaseactivated receptor 4-peptide (PAR4-P); n=10 donors. Statistical significances were calculated using MannWhitney rank-sum test. AU indicates arbitrary units; and AU*min, AUC (area under the curve).
But how does S1P/S1PR 1 control platelet aggregation in response to PAR4 agonists and ADP? PAR4-P dependent irreversible platelet aggregation has been demonstrated to partially rely on subsequent TBXA2 release. 31 We observed that Sphk2-deficient platelets as well as platelets treated with the S1PR 1 antagonist W146 showed an impaired TBXA2 release following stimulation by α-thrombin ( Figures 3B and 6B ). Accordingly, we tested whether addition of the stable TBXA2 analogue U46619 could compensate for the diminished aggregation observed in Sphk2-deficient platelets. Indeed, as shown in Figure 6C , addition of 1 μmol/L exogenous U46619 during PAR4 activation completely rescued the aggregation defect of Sphk2-deficient platelets to a level comparable with the normal aggregation response of WT littermates. Thus, our data suggest that impaired TBXA2 release in Sphk2 null platelets leads to defective PAR4-induced platelet aggregation in a process involving S1PR 1 .
In contrast, TBXA2 generation is unlikely to contribute to enhanced ADP-induced aggregation as blocking of TBXA2 production with cyclooxygenase inhibitors did not affect ADP-induced aggregation in WT platelets (N. Urtz, unpublished data, 2014). Platelet aggregation in response to ADP is mediated by 2 G-protein-coupled receptors, P2Y1 and P2Y12. Since activation of P2Y1 triggers phospholipase C-dependent calcium release from internal stores, we next measured intracellular calcium response in ADP-stimulated Sphk2-deficient platelets. Unexpectedly, we observed no alteration of calcium responses in Sphk2-deficient and control platelets (Online Figure III) , indicating that Sphk2/S1P signaling does not act via modulation of calcium mobilization following ADP activation. Both the ADP receptor P2Y12 and the S1PR 1 couple to G-protein subunit G αi . ADP signaling via P2Y12 plays a crucial role in the activation of platelet α IIb β 3 integrin and subsequent platelet aggregation. Hence, we measured α IIb β 3 integrin activation in WT and Sphk2-deficient platelets by flow cytometry in the presence and absence of platelet agonists ( Figure 6D ). Interestingly, α IIb β 3 integrin activation by ADP stimulation was significantly reduced in Sphk2-deficient compared with WT platelets and likely explains their reduced aggregation after ADP induction ( Figure 6A ). Finally, we tested whether addition of exogenous S1P could compensate for the diminished aggregation observed in Sphk2-deficient platelets after ADP-induced aggregation. Indeed, as shown in Figure 6E , addition of 10 μmol/L exogenous S1P during ADP activation completely , and Sphk2-deficient (white bars) mice was triggered either with collagen (col), protease-activated receptor 4-peptide (PAR4-P), or with adenosine diphosphate (ADP) and aggregation was analyzed; n=10/group. B, Blocking of sphingosine 1-phosphate receptor 1 (S1PR 1 ) decreases thromboxane A2 (TBXA2) release. WT platelets were pretreated with vehicle (ctrl) or with 1 μmol/L W146 and induced with α-thrombin. Release of TBXA2 in the supernatant was analyzed. Values present mean±SEM; n=5/group. C, Exogenous TBXA abolishes PAR4-P-induced impaired aggregation in Sphk2-deficient platelets. Whole blood from WT (black bars) or Sphk2-deficient (white bars) mice were induced either with PAR4-P alone or simultaneously with TBXA2, and aggregation was analyzed. Values present mean±SEM; n=5/group. D, Impaired integrin α IIb β 3 activation of Sphk2-deficient platelets. WT (black bars) and Sphk2-deficient (white bars) platelets were left unstimulated (nonstimulated) or induced with adenosine diphosphate (ADP) and α-thrombin, respectively, and binding of an specific antibody to active α IIb ß 3 was measured by flow cytometry. Shown are the mean values±SD; n=5/group. E, ADP and S1P work synergistically. Whole blood from WT (black bars) or Sphk2-deficient (white bars) mice were induced either with ADP alone or simultaneously with S1P, and aggregation was analyzed. Values present mean±SEM; n=5/group. Statistical significance was calculated using Mann-Whitney rank-sum test. by guest on July 22, 2017 http://circres.ahajournals.org/ Downloaded from rescued the aggregation defect of Sphk2-deficient platelets to a level comparable with the normal aggregation response of WT littermates.
Together, the above in vitro data have at least 3 important implications: (1) the endogenous Sphk2-dependent S1P release by activated platelets fosters PAR4-induced and ADPinduced aggregation, (2) a defective TBXA2 release as well as a diminished α IIb β 3 integrin activation contributes to impaired aggregation of Sphk2 null platelets in response to PAR4-P and ADP, and (3) S1P facilitates ADP-induced aggregation by supporting α IIb β 3 integrin activation.
Sphk2-Deficiency Reduces Arterial Thrombosis in a FeCl 3 Model
Finally, to substantiate the above findings in vivo, we evaluated the role of intrinsic S1P release in platelet aggregation using a mouse arterial thrombosis model. Briefly, we induced arterial thrombosis using ferric chloride (FeCl 3 ) as described 27 and monitored platelet aggregation by intravital microscopy for 1 hour. Consistent with our in vitro findings, loss of Sphk2 provided some protection against arterial thrombosis. Although the frequency of occlusive thrombus formation was only moderately (nonsignificantly) affected in Sphk2-deficient mice compared with WT and Sphk1-deficient mice, thrombus stability was severely impaired in Sphk2 null mutants ( Figure 7A and 7B). After initial occlusion, arteries from Sphk2-deficient mice rapidly re-established blood flow (within 6 minutes), in contrast to the stable thrombus formation observed in WT (19 minutes) and Sphk1-deficient (13 minutes) mice ( Figure 7B ). To further evaluate whether these findings are solely plateletdependent, we reconstituted platelet-depleted WT mice with ). C, Arterial thrombosis formation triggered with FeCl 3 performed in plateletdepleted WT mice transfused either with WT or with Sphk2-deficient platelets. The Kaplan-Meier curve shows the percent of arteries without occlusion as a function of time after injury; n=5/group. Statistical significance was calculated using linear rank test. D, Sphk2-deficient platelets reduce thrombus stability. The duration of occlusion is indicating the thrombus stability. WT mice transfused with WT or with Sphk2-deficient platelets (plts). Values present mean±SEM; n=5/group. Statistical significance was calculated using Mann-Whitney rank-sum test. E, Tail bleeding time measured after transection of the tail tip of WT and Sphk2-deficient mice. Values present mean±SEM; n=8/group. Statistical significance was calculated using Mann-Whitney rank-sum test.
platelets isolated from either WT or Sphk2-deficient mice (Methods in Online Data Supplement). Although mice transfused with WT platelets showed normal thrombus formation after FeCl 3 injury, mice transfused with Sphk2-deficient platelets had a severe reduction in both thrombus incidence, as well as stability ( Figure 7C and 7D) .
These findings clearly establish that intrinsic S1P release through platelet Sphk2 controls platelet aggregation and thrombus growth in vivo. Interestingly, Sphk2 deficiency does not affect physiological hemostasis as indicated by an unaltered tail bleeding time in Sphk2-deficient mice ( Figure 7E ).
Discussion
Platelets are known to produce and release S1P. However, the exact molecular source of platelet S1P and the role of intrinsic S1P generation in platelet function have not been studied in detail. We now report that Sphk2 is the main isoform that generates S1P in platelets and that platelets lacking Sphk2 are unable to secrete S1P into the extracellular space. We show that S1P alone initiates platelet aggregation via the S1PR 1 and that this S1P/S1PR 1 pathway facilitates PAR4-P and ADP-induced aggregation. In addition, Sphk2 null platelets release lower amounts of TBXA2 and show an impaired activation of α IIb β 3 integrin translating into diminished aggregation in response to stimulation with PAR4-P and ADP. Consistent with the aggregation defect of Sphk2-deficient platelets in vitro, loss of platelet Sphk2 protects partially against arterial thrombosis in vivo without affecting hemostasis.
Sphk2-deficient mice do not show an obvious phenotype and pharmacological Sphk2 inhibitors, which are currently tested for treatment of pancreatic cancer in patients, could thus develop into promising new drug tools relevant for various diseases. 32 Therefore, modulating the platelet Sphk2/S1P pathway could represent an interesting novel antithrombotic strategy.
Platelets possess constitutive Sphk activity 33 and lack S1P-lyase, an enzyme that irreversibly degrades S1P. 14, 18 Together, this pattern of enzyme activities leads to the generation and storage of high S1P levels in platelets. Since increased S1P levels are observed in the serum compared with the plasma, 16 ,34 platelets were originally thought to constitute the main rheostat of plasma S1P. However, we show here that loss of Sphk2 does not lead to a reduction in plasma S1P concentration, suggesting that platelet-derived S1P is dispensable for plasma S1P homeostasis. This is in line with several studies demonstrating that red blood cells 13, 17, 18 and endothelial cells 19 act as the primary sources of plasma S1P and are responsible for the establishment of the steep blood-to-tissue S1P concentration gradient in vivo. 35 In line with this notion we observed that Sphk1 is the predominant source of red blood cell-derived S1P, and that loss of Sphk1 is associated with a reduction in plasma S1P concentrations. Hence, our data provide direct evidence that red blood cells not only store and transport S1P generated elsewhere (eg, by endothelial cells) 17, 18, 20 but also act as potent manufacturers of S1P controlling S1P homeostasis in the blood.
Since platelets are dispensable for homeostasis of S1P in blood plasma, what is the role of platelet-derived S1P? The irrelevance of platelet-derived S1P for plasma S1P homeostasis does not exclude a role of this mediator in the intrinsic control of platelet function. Indeed, we show here that activated platelets generate and release S1P into their local microenvironment. In line with this finding, others have reported previously that platelets generate and release S1P after activation with thrombin, collagen, phorbol ester, and to a lesser extent with ADP, 15, 22, [36] [37] [38] suggesting that they likely contribute to the production of local S1P gradients that may have effects on local processes rather than impacting on bulk plasma S1P levels. Platelets are not only essential for primary hemostasis and repair of the endothelium after vascular injury but also act as major cellular players of arterial thrombosis triggering myocardial infarction and stroke. The first step of arterial thrombosis is the adhesion of platelets to exposed extracellular matrix. Our data show that the reduced S1P content of Sphk2-deficient platelets does not influence their ability to adhere to various substrates in a flow chamber model in vitro or in a denudation model of the mouse femoral artery in vivo. Following platelet adhesion, the subsequent steps leading to arterial thrombosis are platelet aggregation and clot formation. Platelet adhesion to immobilized fibrinogen as well as platelet aggregation in the presence of soluble fibrinogen both depend on integrin α IIb β 3 . However, while adhesion to fibrinogen can occur without prior α IIb β 3 activation, aggregation largely depends on inside-out integrin activation. This renders aggregation more susceptible to Sphk2-dependent integrin activation and likely explains why aggregation is affected in null mutants, despite normal platelet adhesion to fibrinogen.
The role of S1P for platelet aggregation and coagulation remains controversial. There is evidence that S1P enhances platelet aggregation by inducing platelet shape change through an increase in phospholipase C activity. 22, 39, 40 Other studies have reported that S1P inhibits rather than supports platelet aggregation. 41 However, the latter data are based on in vitro experiments using washed platelets or platelet-rich plasma. In our present study, we performed whole blood aggregation assays to mimic physiological conditions as closely as possible. Münzer et al 42 recently reported that Sphk1-deficient platelets show elevated degranulation (release of alpha and dense granules) and aggregation in response to low-dose agonist stimulation. Based on their findings, the authors speculated that this was because of reduced levels of intracellular platelet S1P and proposed that platelet S1P acts as a negative regulator of platelet aggregation. However, the authors did not measure platelet S1P levels in Sphk1-deficient platelets in their study. In fact, we show here by liquid-chromatography/mass spectrometry that intracellular S1P levels are not reduced but rather increased in Sphk1-deficient platelets compared with WT controls or Sphk2-deficient mice. Hence, platelet S1P facilitates rather than inhibits platelet activation, explaining the increased aggregation reported in Sphk1-deficient platelets. 42 We show that S1P mainly induces a dose-dependent aggregation response via the S1PR 1 in whole blood. A recent study showed that aggregation of washed human platelets was reduced not only by inhibition of S1PR 1 , but also in the presence of the S1PR 2 antagonist JTE-013 40 . However, washing by guest on July 22, 2017 http://circres.ahajournals.org/ Downloaded from of platelet affects extracellular S1P concentrations, which in turn may have a substantial effect on S1PR surface expression. Hence, the differences between our findings and that obtained by Randriamboavonjy et al are likely explained by the different experimental conditions applied. Notably, we observed no platelet aggregation response when washed platelets were incubated with S1P (N. Urtz, unpublished data, 2009 ). This is in line with previous data from Yatomi et al, 22 who showed that S1P stimulates aggregation only after the addition of exogenous adhesion proteins. In their study, subthreshold concentrations of S1P and weak platelet agonists, such as ADP, synergistically elicit aggregation. Hence, taken together our present findings support the concept that S1P acts as a platelet agonist via S1PR 1 .
During activation, platelets release or translocate a panoply of >300 proteins and lipids. 1, 2, 43 Among the lipid fraction, AA and its metabolite TBXA2, are known to act as intrinsic agonists, supporting platelet aggregation by amplifying the secretion of platelet constituents from lysosomes, α-granules, and dense granules. 3 We show here that both the loss of Sphk2-dependent S1P production by platelets and inhibition of S1PR 1 results in defective agonist-induced TBXA2 release by platelets suggesting that S1P intrinsically controls the generation and release of this AA metabolite. Interestingly however, in the absence of additional platelet agonists, S1P alone fails to activate cyclooxygenase 1 and consequently fail to synthesize and release TBXA2, highlighting its role as a supportive rather than potent agonist facilitating platelet activation (N. Urtz, unpublished data, 2014). Importantly, defective release of TBXA2 results in attenuated aggregability of Sphk2-deficient platelets in response to PAR4-P. Notably, it has been shown that blocking TBXA2 formation results in a failure to release S1P from platelets 36 suggesting a reciprocal crosstalk of 2 agonistic lipid pathways operating in platelets.
Although our data clearly support the role of secreted S1P in amplifying platelet aggregation, S1P might also act as an intracellular second messenger as previously reported for other cell types. 44 We have recently shown that intracellular Sphk2/S1P signaling is required for expression and overall activities of most Src family kinases present in the megakaryocyte/platelet lineage, including Lyn, Fyn, Src, Yes, and Fgr. 23 Indeed, Lyn has been demonstrated to regulate TBXA2-synthesis in platelets. 45 Thus, reduced Lyn expression/activity might further contribute to the reduced TBXA2 release by Sphk2 null platelets. In summary, our present findings identify a novel agonistic signaling pathway downstream of PAR4 receptors, involving Sphk2-dependent S1P release leading to the release of the potent platelet agonist TBXA2 supporting platelet aggregation.
In line with previous reports, we did not detect TBXA2 generation after ADP stimulation in the presence of physiological calcium concentrations. 46 In addition, blocking of TBXA2 synthesis with a cyclooxygenase inhibitor had no impact on ADP-induced aggregation (N. Urtz, unpublished data, 2014). Nevertheless, ADP-induced aggregation of Sphk2-deficient platelets was largely impaired, indicating the existence of additional S1P-dependent regulatory pathways facilitating platelet aggregation independent of TBXA2 release. ADP induces platelet aggregation by activating α IIb β 3 integrin through its receptors P2Y1 (G αq -coupled) and P2Y12 (G αi -coupled). P2Y12 receptor signaling highly depends on phosphoinositide-3 kinase activation and is important for sustained activation of α IIb β 3 as well as irreversible platelet aggregation. 47 In line with this, we found significantly reduced levels of activated integrin α IIb β 3 in Sphk2-deficient platelets following incubation with ADP. Likewise, S1PR 1 is a G αi -coupled receptor and activation of phosphoinositide-3 kinase has been demonstrated to be an important signaling event downstream of S1PR 1 , involved in various cellular functions. 48 Thus, we speculate that platelet intrinsic S1P might amplify ADP-induced platelet activation via S1PR 1 by contributing to phosphoinositide-3 kinase activation and thereby facilitating sustained α IIb β 3 activation. However, we show that Sphk2/S1P-dependent facilitation of ADP-induced platelet aggregation does not involve calcium mobilization. Hence, it is likely that Sphk2/S1P acts via activation of phosphoinositide-3 kinase signaling, which is known to support α IIb β 3 integrin activation and has been reported to act downstream of both P2Y12 and S1PR 1 .
48
The formation and stabilization of a growing hemostatic plug requires the continued full-fledged activation of recruited platelets to prevent those platelets not in direct contact with the wound from loosely associating and eventually detaching from the thrombus. We report here that Sphk2-deficient mice show a reduction in both the extent and duration of occlusion in a FeCl 3 -induced mouse model of arterial thrombosis in vivo. Several mechanisms are likely to act together accounting for the partial protection of Sphk2-deficient mice from arterial thrombosis, including (1) the loss of a potential direct intrinsic agonistic effect of S1P on platelet aggregation, (2) impaired aggregation capacity after PAR4 activation accompanied by decreased secretion of TBXA2 by Sphk2-deficient platelets and hence the loss of this amplifying signal on newly recruited platelets, and (3) the diminished sensitivity to ADP because of the loss of synergy with S1P-mediated signaling.
In summary, we demonstrate here that the release of S1P by activated platelets into their local micromilieu plays a significant role in regulating important platelet functions including secretion and aggregation in vitro and in vivo. We show that Sphk2 is the Sphk responsible for S1P release by platelets, identifying this enzyme as a new key mediator of platelet homeostasis and potential antithrombotic target. However, since our present findings were obtained in mice, future studies will have to evaluate the relevance of Sphk2/S1P signaling in humans. What Is Known?
• Two sphingosine kinase (Sphk) isoforms produce sphingosine 1-phosphate (S1P) which is a physiological component of human and mouse plasma.
• Blood platelets generate, store, and release S1P.
What New Information Does This Article Contribute?
• The Sphk isoform Sphk2 is the major source of S1P in murine platelets.
• Platelet-intrinsic S1P critically regulates platelet function.
• Loss of Sphk2 in platelets protects from arterial thrombosis without affecting hemostasis in vivo.
Platelet aggregation is an essential step during thrombus formation and is regulated by the concerted action of platelet agonists.
Although it is known that platelets produce and secrete the bioactive lipid metabolite S1P on stimulation, the exact molecular source of platelet S1P and its role in platelet function have not been studied in detail. We identified Sphk2 as the major isoform responsible for S1P production in platelets and demonstrated its pivotal intrinsic role during platelet activation. S1P released by activated platelets triggered platelet aggregation via the S1P-receptor 1, thereby critically amplifying the sustained aggregatory response of classical platelet agonists in vitro. Consequently, Sphk2-deficient mice developed unstable thrombi after vascular injury in vivo. While protecting mice from arterial thrombosis Sphk2 deficiency did not affect physiological hemostasis translating in normal bleeding times in Sphk2-deficient animals.
Modulating the platelet Sphk2/S1P pathway could therefore represent an interesting novel antithrombotic strategy.
examined with a Zeiss light microscope. Based on these light microscopic investigations, ultrathin sections from selected tissue blocks were counterstained with uranyl acetate and lead citrate and examined with a Philips CM 10 transmission electron microscope.
Measurement of S1P concentrations
Levels of S1P in plasma and blood cells were determined by high-performance liquid chromatography (HPLC; Agilent, Palo Alto, CA) with mass detection (LC-MS/MS) as previously described 2 . Samples were spiked with internal standard (C17-S1P; Avanti Polar Lipids, Alabaster, IL) and extracted with chloroform/methanol at acidic pH; extracts were subjected to acetylation with acetanhydride in pyridine (40°C, 20 minutes) as described 3 . Following evaporation of solvents, samples were dissolved in methanol/0.2% formic acid and injected onto an Eclipse XDB C 8 column (5µ, 4.6 x 150 mm; Agilent), which was eluted with a gradient at a flow rate of 0.5 mL per minute at 40°C. Species were detected by negative ion electrospray-ionization liquid chromatography with tandem mass spectroscopy (LC-MS/MS) using an API 4000 QTrap instrument (MDS Sciex, Concord, Canada). The optimal collision energy for derivatized S1P and C17-S1P was -28 and -26 V, respectively. The multiple reaction monitoring (MRM) transitions monitored were m/z 462/402 and m/z 448/388, respectively.
Analysis of Sphk1 and 2 activities of platelets and red blood cells
Sphk1 and 2 activities were measured essentially as previously described Platelets adhesion in a flow chamber CFDA-SE-labelled platelets isolated from WT, Sphk1-and Sphk2-deficient mice were perfused for 5 min at a shear rate of 1000s -1 over fllow chamber slides (µ-slides, IbidiIntegrated BioDiagnostics; Martinsried, Germany) consisted of six parallel channels with a volume of 30 µl each which were coated with: murine fibrinogen (10 µg/mL, Invitrogen), human von Willebrand Factor (vWF) (40 µg/mL, Calbiochem), or murine laminin (40 µg/mL, Sigma-Aldrich). An air-driven continuous flow pump system (Ibidi-Integrated BioDiagnostics; Martinsried, Germany) was used that featured computer-assisted direct control of the applied shear rates and mechanical stress on the suspended cells was minimized by generation of the flow via air pressure. The pump connects the multichannel slides in both directions via short tubes with reservoirs that contain the cell suspensions. By alternately switching the airvalves in defined time intervals and applying negative pressure to the reservoirs the pump systems achieves a continuous unidirectional flow. Fluorescently-tagged cells were visualized under flow using a Zeiss Axiotech microscope (20x water immersion objective, W 20x/0.5, Zeiss) with a 100W HBO mercury lamp for epiillumination as reported previously 1, 5 . The area of platelet adhesion on protein-coated slides was measured using Capimage (Zeintl, Heidelberg, Germany).
Whole blood aggregation
Platelet aggregation was analyzed using whole blood by multiplate impedance platelet aggregometry. Lepuridin (50 mg/ml, 1:10) anticoagulated blood was collected from human donors from the forearm vein or from mice intracardially and induced by S1P (0.1, 0.5 , 1 , 10 and 50 µM), PAR4 specific peptide (45 µM final concentration), ADP (7 µM final concentration), collagen (1.2 µg/ml final concentration) or PAR4 peptide and the stable TBXA2 analogue U-46619 (1 µM final concentration) and measured by the Multiplate™ system (Dynabyte, Munich, Germany). Parameter of platelet activity is defined as area under the aggregation curve (AUC) 6, 7 .
Mouse model of arterial denudation
Transluminal mechanical injury of the femoral arteries was induced by a flexible wire as described previously 1, [8] [9] [10] . Mice were anesthetized by intraperitoneal injection as described previously 1 and the femoral arteries were exposed and ligated proximally and distally with silk sutures. After isolating a small arterial branch arterial injury was induced by insertion of a flexible wire (0.36 mm in diameter; Floppy II Guide Wire Guidant Corporation, Diegem, Belgium). Blood flow in the femoral artery was restored by releasing the sutures. Platelets were labelled with rhodamine B and infused intravenously into the jugular vein of WT or Sphk1-and Sphk2-deficient recipients, respectively and intravital microscopy was performed.
Intravital epifluorescence microscopy A high-speed widefield Olympus BX51WI fluorescence microscope with a long-distance condenser and ax ×20 (NA 0.95) water-immersion objective was used for intravital imaging. The system is equipped with an Olympus MT 20 monochromator for excitation and a F-View CCD camera (Olympus). Olympus Cell/R software was used for synchronization of components, data acquisition, and image analysis. Cells that were immotile for 30 seconds were counted as adherent, as described 11 . The platelet-covered area (mm 2 ) was determined by planimetric measurement (Cap-Image 7.1).
Assessment of arterial thrombosis after ferric chloride exposure
Vascular injury of the carotid artery was induced by local application of ferric chloride (FeCl 3 ) essentially as described 9, 12 . Control (WT) or Sphk1-and Sphk2-deficient mice were anaesthetized by intraperitoneal injection as described previously 1 and fluorescently-labelled platelets were infused intravenously into the jugular vein of WT or Sphk1-and Sphk2-deficient recipients, respectively. Thereafter, the common carotid artery was dissected free and a filter paper (0.5 x 1.0 mm) saturated with 10% FeCl 3 was applied to the adventitial surface of the vessel, as previously described 12 . We monitored the blood flow in the vessel by in vivo video microscopy for the duration of the experiment (60 minutes) after removal of the ferric chloride saturated filter paper. The time to thrombotic occlusion of the carotid artery downstream of the site of injury was defined as the time required for complete arrest of blood flow in the center of the vessel (platelet flow velocity 0 m/s). The duration of occlusion is indicated as time span starting from first point of occlusion (defined as the time required for complete arrest of blood flow) until to a re-established blood flow, indicating the thrombus stability. Additionaly we depleted WT mice completely from circulating platelets by i.v. (tail vein) injection of polyclonal anti-glycoprotein Ibα antibodies. After 48 hours (when the anti-GP Ibα antibody was eliminated but before new platelets were generated) platelet-depleted WT mice were transfused with platelets isolated from either WT or Sphk2-deficient mice and the platelet counts were adjusted to 300 / nl -an amount sufficient for vascular occlusion caused by arterial thrombus formation 13 -and vascular injury of the carotid artery was performed as described above.
Bleeding time
Bleeding time was examined using the tail -tip transection technique. Briefly, mice were anesthetized and placed on a 37°C homeothermic blanket. After transection of a 5 mm tailtip segment, the tail was immediately immersed in saline (37°C, constant temperature) and the time to bleeding cessation was measured.
Calcium measurements
Platelets were isolate from WT or Sphk2-deficient mice, respectively and loaded with 4 µM Fura-2 acetoxymethylester (Sigma-Aldrich) at room temperature for 25 minutes in the dark. Loaded platelets were resuspended in Tyrode`s solution either containing 3 mM EGTA (to inhibit the extracellular calcium influx) or 2 mM calcium (final concentration). The platelets were seeded in clear-bottom 96-well plates at a density of 5×10 6 cells per well and stimulated by automatically injection of α-thrombin (0.1 U/ml final concentration) or ADP (10µM final concentration) after 10 seconds. Fluorescence responses at alternating excitation wavelengths of 340 and 380nm were measured at room temperature in a PolarSTAR plate reader obtained from BMG (Offenburg, Germany) according to the manufacturer's protocol. The free calcium levels were monitored from the changes in the fluorescence ratio produced by excitation at 340 and 380 nm.
Flow cytometric analysis of activation of the α IIb β3 integrin
The activation of α IIb β3 integrin in platelets isolated from WT and Sphk2-deficient animals was assessed with R-phycoerythrin-conjugated JON/A antibody (JON/A-PE; Emfretanalytics, Germany) which particullary binds to the active but not the resting conformation state of the integrin, whereas polyclonal rat IgG-PE (Emfret-analytics, Germany) served as negative control. 1x10 6 resting, ADP-(10 µM) or α-thrombin-(0.1 U/ml) activated platelets were stained with JON/A (1:100) in the present of 1 mM calcium / magnesium and analyzed using a Beckmann Coulter Gallios TM flow cytometer system.
Statistical Analysis
Mann-whitney rank sum-test for unpaired data was used to compare groups unless indicated otherwise. To assess statistical significance of Kaplan-Meier curves the linear rank test was used 
